Neurological conditions and diseases impose an enormous clinical and social burden globally, and affect approximately 200 million people in the U.S., Europe and Japan (according to Business Insights analysis). These include acute trauma or ischemic injury conditions such as stroke, traumatic brain injury, and spinal cord injury, as well as episodic, chronic or progressive neurological conditions like depression, schizophrenia, epilepsy, Parkinson’s Disease, Multiple Sclerosis, Alzheimer’s Disease, migraine, ADHD and other conditions. For many neurological conditions there are few effective therapeutic options available, and the field is an intense area of research and development among major pharmaceutical and biotechnology companies.